Dexmethylphenidate
| d-MPH | |
|---|---|
| Salts [] | |
|---|---|
| Dexmethylphenidate hydrochloride | |
| Molecular structure drawn from PubChem coordinates |
| Physical properties [] | |
|---|---|
| Molecular mass | 233.31 g/mol [1] |
| Melting point | >203 [1] |
| Predicted LogP | 0.2 [1] |
| Structural Identifiers [] | |
|---|---|
| Molecular formula | C14H19NO2 |
| IUPAC name | methyl (2R)-2-phenyl-2-[(2R)-piperidin-2-yl]acetate |
| SMILES | COC(=O)[C@@H]([C@H]1CCCCN1)C2=CC=CC=C2 |
| InChI | InChI=1S/C14H19NO2/c1-17-14(16)13(11-7-3-2-4-8-11)12-9-5-6-10-15-12/h2-4,7-8,12-13,15H,5-6,9-10H2,1H3/t12-,13-/m1/s1 |
| InChIKey | DUGOZIWVEXMGBE-CHWSQXEVSA-N |
| CAS number | 40431-64-9 |
| UNII | M32RH9MFGP |
| PubChem CID | 154101 |
| Pharmacokinetics[] | |
|---|---|
| Elimination half-life | 4 hours |
| Metabolism | Liver |
| Excretion | Kidney |
| Routes of administration | By mouth |
| Dependence liability | Physical: None, Psychological: Moderate[3] |
| Addiction liability | Moderate |
| Dosing[] |
|---|
| Buccal [] | |
|---|---|
| Light | ≤ 31.6 mg(12x - 33.3%) |
| Common | 31.6 - 40 mg(8x - 22.2%) |
| Strong | 40 - 60 mg(10x - 27.8%) |
| Heavy | 60 - 85 mg(2x - 5.6%) |
| Extreme | 85 mg +(4x - 11.1%) |
| Insufflated [] | |
|---|---|
| Light | ≤ 32.7 mg(76x - 30.4%) |
| Common | 32.7 - 40 mg(64x - 25.6%) |
| Strong | 40 - 60 mg(49x - 19.6%) |
| Heavy | 60 - 116.3 mg(35x - 14.0%) |
| Extreme | 116.3 mg +(26x - 10.4%) |
| Intravenous [] | |
|---|---|
| Light | ≤ 8.8 mg(1x - 25.0%) |
| Common | 8.8 - 10 mg(2x - 50.0%) |
| Strong | 10 - 15 mg |
| Heavy | 15 - 24 mg |
| Extreme | 24 mg +(1x - 25.0%) |
| Subcutaneous [] | |
|---|---|
| Light | ≤ 40.9 mg(2x - 66.7%) |
| Common | 40.9 mg |
| Strong | 40 - 50 mg |
| Heavy | 50 - 56 mg |
| Extreme | 56 mg +(1x - 33.3%) |
| Sublingual [] | |
|---|---|
| Light | ≤ 34.5 mg(74x - 27.2%) |
| Common | 34.5 - 40 mg(80x - 29.4%) |
| Strong | 40 - 60 mg(53x - 19.5%) |
| Heavy | 60 - 98 mg(37x - 13.6%) |
| Extreme | 98 mg +(28x - 10.3%) |
| Oral [] | |
|---|---|
| Light | ≤ 24.8 mg(122x - 43.1%) |
| Common | 24.8 - 36 mg(37x - 13.1%) |
| Strong | 36 - 72 mg(57x - 20.1%) |
| Heavy | 72 - 108 mg(40x - 14.1%) |
| Extreme | 108 mg +(27x - 9.5%) |
Statistically derived dosages via DBI-IGS (archived by anodyne.wiki) We do not take any responsibility for medical complications or loss of life sustained by following these dosages blindly. |
Dexmethylphenidate (also known as d-threo-Methylphenidate, (+)-threo-Methylphenidate, dexmetilfenidato, Attenade, D-tmp, dexmethylphenidatum, methyl (R)-phenyl[(R)-piperidin-2-yl]acetate, methyl (2R)-phenyl[(2R)-piperidin-2-yl]acetate, 2-Piperidineacetic acid, α-phenyl-, methyl ester, (αR,2R)- or Methyl (2r)-phenyl((2r)-piperidin-2-yl)acetate) is a stimulant substance of the phenidate class.
Chemistry
Salts []
Stereochemistry []
Dexmethylphenidate is a single defined stereoisomer.
Druglikeness
Lipinski's rule of five
Dexmethylphenidate matches Lipinski's rule of five.Pharmacology
ATC Classification
- nervous system (N)
- psychoanaleptics (N06)
- psychostimulants, agents used for adhd and nootropics (N06B)
- centrally acting sympathomimetics (N06BA)
- dexmethylphenidate (N06BA11)
MeSH Classification
Mechanism of action []
Methylphenidate inhibits dopamine and norepinephrine reuptake transporters in synapses, especially in the thalamus and striatum. One study shows no detectable difference in the caudal prefrontal cortex of treated or untreated monkeys, though multiple rat studies show activity on the prefrontal cortex. Imaging of human brains after administration of methylphenidate shows changes to blood flow of various regions of the brain including the striatum, supplementary motor area, and posterior parietal cortex. [1]
Subjective effects []
Experience reports
Legal status []
- Australia: Dexmethylphenidate is a Schedule 8.
- Canada: Dexmethylphenidate is a Schedule III.
- Germany: Dexmethylphenidate is a Anlage III under the "Betäubungsmittelgesetz (BtMG)".
- United Kingdom: Dexmethylphenidate is a Class B under the "Misuse of Drugs Act 1971".
- United States: Dexmethylphenidate is a Schedule II under the "Controlled Substances Act".
- United Nations: Dexmethylphenidate is a Schedule II psychotropic under the "Convention on Psychotropic Substances 1971".
- Other: Dexmethylphenidate is a Rx-only.
See also []
External links []
- Dexmethylphenidate (Wikipedia)
- Dexmethylphenidate (PubChem)
- Dexmethylphenidate (Wikidata)
- Dexmethylphenidate (DrugBank)
- Dexmethylphenidate (ChEMBL)
- Dexmethylphenidate (ChEBI)
- Dexmethylphenidate (Common Chemistry)
- Dexmethylphenidate (HMDB)
- Dexmethylphenidate (KEGG)
- Dexmethylphenidate (EPA DSSTox)
- Dexmethylphenidate (Effect Index)
- Dexmethylphenidate (UNII)
References []
National Center for Biotechnology Information. PubChem Compound Summary for CID 154101, Dexmethylphenidate. Accessed November 20, 2026. https://pubchem.ncbi.nlm.nih.gov/compound/154101
U.S. Food and Drug Administration; National Center for Advancing Translational Sciences. Dexmethylphenidate. UNII: M32RH9MFGP. Global Substance Registration System. Accessed November 20, 2026. https://gsrs.ncats.nih.gov/ginas/app/beta/substances/M32RH9MFGP
Stahl SM. Prescriber's Guide: Stahl's Essential Psychopharmacology. Cambridge University Press. April 2024.
Data sources []
| Source | Status | Updated (UTC) |
|---|---|---|
| dosing | ok | 2026-11-20 06:08:15 |
| drugspro | missing (no DrugsPRO reagent data) | 2026-11-20 06:08:11 |
| erowid | missing (no Erowid substance of that name) | 2026-11-20 06:08:11 |
| gsrs | ok | 2026-11-20 06:08:12 |
| hmdb | missing (hmdb.ca refused automated access to HMDB0015647) | 2026-11-20 06:08:11 |
| kegg | ok | 2026-11-20 06:08:14 |
| pubchem | ok | 2026-11-20 06:08:11 |
| ok | 2026-11-20 06:08:11 | |
| sider | missing (not in SIDER) | 2026-11-20 06:08:11 |
| structure | ok | 2026-11-20 06:08:11 |
| wikipedia | ok | 2026-11-20 06:08:11 |